Dr. Moore on the Results of the NOVA Trial in Ovarian Cancer

Kathleen N. Moore, MD, assistant professor, The Stephenson Cancer Center, The University of Oklahoma, discusses the results of the NOVA trial in ovarian cancer.

In the germline BRCA-mutated group, there was a statistically significant positive hazard ratio in favor of niraparib (Zejula), says Moore.

The exploratory endpoints of this trial were to further characterize the germline BRCA-mutated group. A small group of patients with somatic BRCA mutations was identified and they seemed to get the same benefit from niraparib as the BRCA-mutated patients, Moore adds.